Massin E K
Division of Transplantation, Texas Heart Institute, St. Luke's Episcopal Hospital, Baylor College of Medicine, University of Texas Medical School, Houston, Texas.
Tex Heart Inst J. 1991;18(1):41-9.
Within the last decade, the treatment for patients with dilated cardiomyopathy has changed. Clinical management of these patients is aimed at controlling congestive heart failure, treating arrhythmias, preventing pulmonary and systemic emboli, and managing chest pain. The goals of treatment for patients with dilated cardiomyopathy are to make the patient feel better and live longer. To achieve this, we direct treatment to improving left ventricular function and cardiac output and controlling arrhythmias and thromboemboli. Basic treatment begins with inotropic therapy, preload reduction, and afterload reduction. For patients with symptomatic disease, we recommend diuretics, digoxin, and converting enzyme inhibitors for first-line therapy. Patients with arrhythmias may be treated by the addition of amiodarone, a pacemaker, or an automatic implantable cardioverter-defibrillator; and most such patients need to be anticoagulated. All patients need close follow-up for possible drug toxicity associated with their regimens. Heart transplantation can be considered for patients refractory to medical treatment. Although the incidence of dilated cardiomyopathy continues to increase, we are learning better ways to treat it. In the future, new drugs with fewer side effects should be available to treat, and perhaps impede, the development of dilated cardiomyopathy.
在过去十年中,扩张型心肌病患者的治疗方法发生了变化。这些患者的临床管理旨在控制充血性心力衰竭、治疗心律失常、预防肺栓塞和全身性栓塞以及处理胸痛。扩张型心肌病患者的治疗目标是让患者感觉更好并延长寿命。为实现这一目标,我们将治疗方向指向改善左心室功能和心输出量以及控制心律失常和血栓栓塞。基础治疗始于正性肌力治疗、降低前负荷和降低后负荷。对于有症状的患者,我们推荐利尿剂、地高辛和转换酶抑制剂作为一线治疗。心律失常患者可通过加用胺碘酮、起搏器或植入式自动心脏复律除颤器进行治疗;并且大多数此类患者需要抗凝。所有患者都需要密切随访,以观察与其治疗方案相关的可能的药物毒性。对于药物治疗无效的患者可考虑心脏移植。尽管扩张型心肌病的发病率持续上升,但我们正在学习更好的治疗方法。未来,应该会有副作用更少的新药来治疗,甚至可能阻止扩张型心肌病的发展。